

OPEN ACCESS

EDITED BY

Takahisa Hiramitsu, Japanese Red Cross Nagoya Daini Hospital. Japan

REVIEWED BY

Mehmet Taner Ünlü, Health Science University Istanbul Sisli Hamidiye Etfal Training And Research Hospital, Türkiye Kyriakos Vamvakidis, Henry Dunant Hospital, Greece

*CORRESPONDENCE

Yongjie Sun

✓ senasun2005@163.com

Chong Geng

✓ chonggeng_1982@163.com

[†]These authors have contributed

equally to this work
RECEIVED 17 March 2025
ACCEPTED 19 August 2025

PUBLISHED 03 September 2025

CITATION

Liu K, Wang N, Zhao P, Zhao B, Wang Z, Sun Y and Geng C (2025) Preoperative serum indicators as predictors of postoperative hypoparathyroidism following thyroidectomy. *Front. Endocrinol.* 16:1594781. doi: 10.3389/fendo.2025.1594781

COPYRIGHT

© 2025 Liu, Wang, Zhao, Zhao, Wang, Sun and Geng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Preoperative serum indicators as predictors of postoperative hypoparathyroidism following thyroidectomy

Kailin Liu^{1†}, Nana Wang^{2†}, Peng Zhao¹, Baoyan Zhao¹, Zhihao Wang¹, Yongjie Sun^{2*} and Chong Geng 60^{1*}

¹Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China, ²Second Department of Breast Diseases, Second Department of Thyroid Diseases, Shandong Second Provincial General Hospital No. 4, Jinan, Shandong, China

Background: Hypoparathyroidism is a frequent complication following thyroidectomy. However, the risk factors for postoperative hypoparathyroidism remain poorly characterized. This study aims to investigate routine clinical characteristics to identify predictors of postoperative hypoparathyroidism.

Methods: A retrospective analysis was conducted on 3,638 patients who underwent total or hemithyroidectomy with isthmusectomy through open surgery with routine central lymph node dissection. Based on postoperative serum parathyroid hormone(PTH) levels, patients were subdivided according to the normal reference PTH levels or the Q3 quartile of PTH decline rate. Spearman correlation analysis and stepwise multiple linear regression were used to identify factors affecting preoperative serum PTH levels. Univariate and multivariate logistic regression analyses were performed to explore risk factors for postoperative hypoparathyroidism.

Results: Among patients developed postoperative hypoparathyroidism. Multivariate logistic regression revealed that Hashimoto's thyroiditis (HT) (OR=1.786, P=0.007) and preoperative blood glucose (OR=1.319, P=0.005) was an independent risk factor, while body mass index (BMI) \geq 24 (OR=0.714, P=0.032), elevated preoperative PTH levels (OR=0.988, P=0.013) and male (OR=0.554, P=0.002) were protective factors. Among patients in the Q3 quartile, postoperative PTH decline rate was positively associated with HT (OR=2.266, P<0.001), preoperative PTH levels (OR=1.032, P<0.001), and blood glucose (OR=1.234, P=0.027), while it was negatively associated with BMI \geq 24 (OR=0.611, P=0.013), hemoglobin (OR=0.984, P=0.003), and high-density lipoprotein cholesterol (HDL-C) (OR=0.426, P=0.007). Additionally, male (OR=0.558, P=0.003) and preoperative serum Ca²⁺ levels (OR=0.110, OR=0.011) were negatively correlated with the postoperative PTH decline rate in patients undergoing hemithyroidectomy with isthmusectomy. Furthermore, age had no significant effect on the incidence of postoperative hypoparathyroidism.

Conclusions: This study demonstrates that preoperative high glucose levels and HT are risk factors for hypoparathyroidism after total thyroidectomy, while

BMI≥24 serves as a protective factor against postoperative hypoparathyroidism. Additionally, female is a risk factor for hypoparathyroidism after both total thyroidectomy and hemithyroidectomy with isthmusectomy, while higher hemoglobin levels and HDL-C are negatively correlated with the decline in PTH levels after total thyroidectomy.

KEYWORDS

postoperative hypoparathyroidism, parathyroid gland, parathyroid hormone, thyroidectomy, predictors

1 Introduction

Hypoparathyroidism is a frequent complication following thyroidectomy, characterized by a severe deficiency of parathyroid hormone (PTH). Clinical manifestations of hypoparathyroidism include numbness in the lips and limbs, laryngeal spasm, and respiratory muscle paralysis, all of which significantly impair the quality of life of patients or even are life-threatening. Currently, there is no effective treatment for post-surgical hypoparathyroidism. Despite numerous advancements in surgical techniques, hypoparathyroidism remains a challenge in the field of thyroidectomy (1-3). The incidence of transient hypoparathyroidism ranges from 19% to 38%, and that of permanent hypoparathyroidism varies from 0% to 3% (4). Besides external factors related to surgical procedures such as vascular damage or accidental removal, some studies have indicated that age, sex, and Hashimoto's thyroiditis are associated with the occurrence of postoperative hypoparathyroidism, suggesting that preoperative status of the parathyroid glands is an important factor (5-7). Some intrinsic factors of the parathyroid glands, such as preoperative parathyroid function, resistance to damage, and recovery ability may also be critical in determining postoperative parathyroid function.

The preoperative status of the parathyroid glands is regulated by various factors. In addition to the direct factors such as 25-hydroxyvitamin D₃, serum calcium, and phosphorus, recent evidence has shown that waist circumference, BMI, blood glucose (GLU) plasma triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), and leptin levels can also influence parathyroid function (8–11). However, whether these factors also influence the parathyroid glands' resistance to damage during surgery remains unclear, and existing research remains controversial.

Additionally, due to the high heterogeneity in preoperative PTH levels among patients and the wide range of reference normal PTH levels, some patients suffering significant PTH declines but remain within the reference range, previous studies may overlook these patients with significant PTH declines. Therefore, in this study, we introduced a new threshold method based on the decline rates of PTH levels to investigate the key factors influencing parathyroid function, and identifying the potential risk factors for hypoparathyroidism after thyroidectomy. This study may provide

a predictive information for clinical practice, helping the surgeons to perform necessary preventive measures to minimize its incidence.


2 Materials and methods

2.1 Patients

This retrospective study analyzed the medical records of 3,638 patients with thyroid cancer who underwent (1) Total thyroidectomy (thyroidectomy with bilateral central neck dissection) (2), Hemithyroidectomy with isthmusectomy (lobectomy with isthmusectomy combined with ipsilateral central neck dissection including pretracheal and ipsilateral paratracheal) at the Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, from January 2022 to November 2024. Patients were excluded from this study if they met any of the following criteria: previous history of thyroid or parathyroid surgery, presence of preoperative parathyroid dysfunction, presence of diseases affecting bone and lipid metabolism, or incomplete clinical data. All patients underwent open surgery with routine central lymph node dissection.

2.2 Serum PTH level measurement

Fasting serum samples were collected from patients two days before surgery and one day after surgery. Serum PTH levels were measured using an electrochemiluminescence immunoassay (Roche 801). The normal range for serum PTH was 15–65 pg/mL according to the guidelines. We analyzed the factors influencing postoperative parathyroid function. To avoid potential confounding factors, we first categorized the patients into two groups according to surgery type: total thyroidectomy group and hemithyroidectomy with isthmusectomy (Figure 1). In the total thyroidectomy group, 768 eligible patients were included, including 614 females and 154 males, with a mean age of 45.87 ± 11.39 years. We employed two threshold methods to evaluate the decline in postoperative parathyroid functions: (1) the occurrence of postoperative



hypoparathyroidism, (2) the Q3 quartile of the rates between postoperative and preoperative PTH levels. Based on the serum PTH levels, patients were divided into two groups: the normal PTH group and the hypoparathyroidism group (serum PTH<15 pg/mL). Additionally, the postoperative PTH decline rate was calculated by (preoperative-postoperative)/preoperative PTH levels, referred to as relative postoperative PTH reduction. Patients were further categorized into two subgroups: significant decline group (>Q3) and mild decline group (<Q3).

2.3 Clinical characteristics measurement

Preoperative examinations included serum calcium (Ca²⁺), thyroid function, neck ultrasound, and laryngoscopy. Serum samples were collected two days before and one day after surgery. An automated biochemical analyzer (Beckman AU5800) was used to measure the levels of aspartate transaminase (AST), alanine transaminase (ALT), total bile acid (TBA), total protein (TP), albumin (ALB), triglycerides (TG), total cholesterol (TC), HDL-C, low-density lipoprotein cholesterol (LDL-C), free fatty acids (FFA), blood glucose (GLU), creatinine (CREA), and retinol-binding protein (RBP). Abbott chemiluminescence immunoassay (Alinity i) was used to detect the levels of Free Triiodothyronine(FT3), Free Thyroxine (FT4), and Thyroid-Stimulating Hormone (TSH). Electrochemiluminescence immunoassay (Roche801) was used to detect the levels of TG antibody (TGAb), TPO antibody (TPOAb),

and TR antibody (TRAb). Patients with TPOAb≥36 were considered as Hashimoto's thyroiditis(HT).

2.4 Statistical analysis

Statistical analysis was performed using SPSS software(version 27.0). P<0.05 (two-sided) was considered statistically significant. The Shapiro-Wilk test was used to assess the normal distribution of data. Normally distributed data were expressed as mean ± SD, and between-group comparisons were performed using independent sample t-tests. Non-normally distributed data were expressed as median (interquartile range), and between-group comparisons were performed using the Mann-Whitney U test. Categorical variables were expressed as frequencies and percentages, and between-group differences were analyzed using Pearson's χ^2 test with continuity correction. Spearman's correlation analysis was used to determine variables significantly correlated with serum PTH. Use univariate linear regression analysis to examine the association between clinical examination variables and preoperative serum PTH levels and their changes. Stepwise regression (P<0.10) was used to select variables for the multivariate regression model to identify independent influencing factors. Univariate linear regression analysis was performed to examine associations between clinical examination variables and postoperative serum PTH levels and changes. Multivariate logistic regression analysis was performed using the backward likelihood ratio (LR) test. Results of multivariate

logistic regression were expressed as odds ratios (*ORs*) and 95% confidence intervals (*CIs*). A multivariate predictive model was established, and its predictive performance was evaluated using the receiver operating characteristic (ROC) curve and the area under the curve (AUC).

3 Results

3.1 Baseline characteristics of the included patients

After reviewing the medical records of a total of 3,638 patients with thyroid cancers in our hospital and 2,034 patients meeting the inclusion criteria as indicated in the method section were analyzed (Figure 1). Among them, 1,588 were female, and 446 were male, with an average age of 44.90 \pm 11.37 years. The average BMI was 25.13 \pm 3.83, preoperative PTH was 46.58 \pm 15.77 pg/mL, plasma FFA was 0.41 \pm 0.19 mmol/L, TSH was 2.01 \pm 1.88 μ IU/mL, RBP was 34.46 \pm 7.97 mg/L, and Ca²⁺ was 2.33 \pm 0.09 mmol/L (Table 1).

3.2 Factors influencing preoperative parathyroid functions

We firstly analyzed the factors which may influence the preoperative parathyroid functions. Spearman correlation analysis was used to identify variables significantly associated with preoperative serum PTH levels, as shown in Table 2. We found that the preoperative serum PTH levels were positively correlated with BMI (R=0.127, P<0.001), Weight (R=0.1, P<0.001), FFA (R=0.165, P<0.001), and GLU (R=0.053, P=0.016); and negatively correlated with FT3 (R=-0.049, P=0.027), TPOAb (R=-0.048, P=0.03), TP (R=-0.065, P=0.004), HDL-C (R=-0.049, P=0.026), and RBP (R=-0.062, P=0.005) (Figure 2).

Based on comprehensive stepwise regression analysis and clinical practice, this study included the following 12 factors revealed from univariate regression analysis (Supplementary Table S1) for multiple linear regression analysis. The results showed that preoperative serum PTH levels were positively correlated with FFA (β =0.177, P<0.001), BMI (β =0.152, P<0.001), TSH (β =0.059, P=0.006), and FT4 (β =0.047, P=0.033), while negatively correlated with RBP (β =-0.049, P=0.036) and Ca²⁺ (β =-0.235, P<0.001) (Table 3).

3.3 Factors influencing postoperative parathyroid functions

3.3.1 Total thyroidectomy subgroup

The difference in postoperative clinical characteristics between normal and hypoparathyroidism patients are shown in Table 4. Using the first method, based on the occurrence of postoperative hypoparathyroidism, 364 patients (47.4%) remained within the normal postoperative serum PTH range, while 404 (52.6%)

developed hypoparathyroidism. Considering the high heterogeneity in preoperative PTH levels among individuals and wide range of reference PTH levels, relying solely on reference PTH levels to identify the risks for postoperative hypoparathyroidism may overlook patients with significant PTH declines but remain within the reference range. Therefore, we employed two threshold methods to evaluate the decline in postoperative parathyroid function as described in the methods section.

Using the first method, univariate logistic regression analysis revealed 8 variables significantly associated with the occurrence of hypoparathyroidism (P<0.05, Supplementary Table S2, left). Multivariate logistic regression analysis was conducted on variables with P<0.1 in univariate analysis to identify independent risk factors for postoperative hypoparathyroidism. As shown in (Figure 3A), HT (OR=1.786, 95% CI: 1.168-2.731, P=0.007), and GLU (OR=1.319, 95% CI:1.089-1.597, P=0.005) were identified as independent risk factors for postoperative hypoparathyroidism, while BMI \geq 24 (OR=0.714, 95% CI: 0.524-0.971, P=0.032), elevated preoperative PTH levels (OR=0.988, 95% CI: 0.979-0.998, P=0.013) and male (OR=0.554, 95% CI: 0.381-0.805, P=0.002) were protective factors.

Using the second method, based on the Q3 quartile of the rates between postoperative and preoperative PTH levels, a total of 576 patients (75%) were classified into the mild decrease group (<Q3), while 192 patients (25%) were classified into the significant decrease group (>Q3) (Table 4). Univariate logistic regression analysis revealed 6 variables that were significantly associated with the significant decline in PTH levels after total thyroidectomy. Multivariate logistic regression analysis on variables with P<0.1 in univariate analysis (Supplementary Table S2, right) revealed that FT4 (OR=1.098, 95% CI:1.008-1.197, P=0.033), HT (OR=2.266, 95% CI: 1.451-3.538, P<0.001) and GLU (OR=1.234, 95% CI:1.024-1.488, P=0.027) were independent risk factors for significant postoperative PTH decline. BMI≥24 (OR=0.611, 95% CI: 0.414-0.902, P=0.013), Hemoglobin (OR=0.984, 95% CI: 0.973-0.995, P=0.003) and HDL-C (OR=0.426, 95% CI: 0.229-0.792, P=0.007) were identified as protective factors (Figure 3B). The area under the ROC curve (AUC) of the multivariable combined model was 0.698 (95% CI: 0.655-0.742), while that of preoperative PTH alone was 0.649 (95% CI:0.605-0.694) (Supplementary Figure S1A).

3.3.2 Hemithyroidectomy with isthmusectomy subgroup

Among 1,055 patients undergoing hemithyroidectomy with isthmusectomy, only 69 (6.44%) of these patients showed postoperative PTH levels below the normal reference range. Therefore, we focused on the second method, which resulted in 777 patients (75%) in the mild decline group and 278 (25%) in the significant decline group (Table 5). Multivariate logistic regression analysis on variables with P < 0.1 in univariate analysis (Supplementary Table S3) indicated that male (OR = 0.558, 95% CI: 0.380-0.819, P = 0.003) and serum Ca^{2+} levels (OR = 0.110, 95% CI: 0.020-0.605, P = 0.011) were negatively associated with postoperative PTH decline, while preoperative serum PTH levels (OR = 1.036, 95% CI: 1.026-1.045, P < 0.001) were positively

TABLE 1 Clinical characteristics of patients.

N=2034 Mean (SD) 15.00-78.00 44.90 (11.37) Age (years) Height (m) 1.47-1.91 1.64 (0.07) Weight (kg) 35.00-140.00 68.29 (13.28) BMI (kg/m²) 14.76-43.21 25.13 (3.83) Erythrocyte (10^12/L) 2.51-5.85 4.41 (0.43) Hemoglobin (g/L) 68 00-176 00 129.35 (16.32) FT3 (pmol/L) 1 77-9 03 4.26 (0.5) FT4 (pmol/L) 1.06-44.44 12.35 (1.79) TSH (μIU/mL) 0.01- 49.61 2.01 (1.88) TGAb (IU/mL) 10.00 -4000.00 90.21 (320.44) TPOAb (IU/mL) 9.00-600.00 38.25 (96.02) TRAb (IU/L) 0.80-40.00 0.89 (1.12) AST (U/L) 20.94 (17.57) 2.00-725.00 ALT (U/L) 1.00-755.00 20.26 (22.68) TBA $(\mu mol/L)$ 0.30-72.40 5.08 (4.41) TP (g/L) 52.60-87.00 68.79 (4.72) ALB (g/L) 30.20-97.30 41.26 (3.34) TG (mmol/L) 0.33-44.58 1.42 (1.41) TC (mmol/L) 1.93-52.90 4.76 (1.44) HDL C (mmol/L) 1 32 (0 31) 0.45-2.66 LDL_C (mmol/L) 2.95 (0.75) 0.71-6.45 FFA (mmol/L) 0.07 -1.46 0.41 (0.19) GLU (mmol/L) 3.02-13.98 4.67 (0.87) CREA (µmol/L) 32.10-163.50 57.21 (11.71) RBP (mg/L) 17.60-73.50 34.46 (7.97) Pre_Ca2+ (mmol/L) 2.09-2.78 2.33 (0.09) Pre_PTH (pg/mL) 14.41-124.60 46.58 (15.77)

Preoperative Ca2+ (Pre_Ca2+), Preoperative PTH (Pre_PTH).

associated (Figure 3C). The area under the ROC curve (AUC) of the multivariable combined model was 0.668 (95% CI: 0.631-0.706), while that of preoperative PTH alone was 0.683 (95% CI: 0.646-0.720) (Supplementary Figure S1B). Given that hemithyroidectomy does not affect the contralateral glands, these preoperative indicators may be also associated with an insufficient compensatory capacity of the contralateral gland(s).

4 Discussion

Hypoparathyroidism is a frequent complication following thyroidectomy (12). In this study, we employed two methods to define hypoparathyroidism and to identify preoperative risk factors for postoperative hypoparathyroidism in patients undergoing total

TABLE 2 Preoperative PTH spearman correlation analysis.


N=2034	R	Р
Age (years)	-0.013	0.544
Height (m)	-0.008	0.714
Weight (kg)	0.100**	<0.001
BMI (kg/m²)	0.127**	<0.001
Erythrocyte (10^12/L)	0.001	0.950
Hemoglobin (g/L)	-0.041	0.063
FT3 (pmol/L)	-0.049*	0.027
FT4 (pmol/L)	0.029	0.187
TSH (μIU/mL)	0.037	0.097
TGAb (IU/mL)	-0.038	0.084
TPOAb (IU/mL)	-0.048*	0.030
TRAb (IU/L)	0.043	0.052
AST (U/L)	-0.025	0.267
ALT (U/L)	0.007	0.765
TBA (μmol/L)	0.017	0.446
TP (g/L)	-0.065**	0.004
ALB (g/L)	-0.036	0.103
TG (mmol/L)	0.009	0.681
TC (mmol/L)	-0.032	0.149
HDL_C (mmol/L)	-0.049*	0.026
LDL_C (mmol/L)	-0.017	0.439
FFA (mmol/L)	0.165**	<0.001
GLU (mmol/L)	0.053*	0.016
CREA (µmol/L)	-0.018	0.408
RBP (mg/L)	-0.062**	0.005
Pre_Ca ²⁺ (mmol/L)	-0.230**	<0.001

Preoperative Ca2+ (Pre_Ca2+).

*P < 0.05. **P < 0.01.

thyroidectomy or hemithyroidectomy with isthmusectomy. Although surgical technique is considered a direct factor influencing postoperative hypoparathyroidism, our study still revealed significant associations between this complication and certain specific clinical indicators.

In the total thyroidectomy group, we found that preoperative high glucose levels are a risk factor for postoperative hypoparathyroidism, while high BMI is a protective factor for postoperative hypoparathyroidism in both methods to define the decline of parathyroid function. Additionally, preoperative high PTH levels were identified as an independent risk factor for a significant postoperative PTH decline. Although we identified preoperative high glucose levels and elevated preoperative PTH levels as independent risk factors, these two may be interrelated, as preoperative serum PTH levels have been reported to positively



correlate with blood glucose levels (13–15). The elevated glucose levels seem to be a consequence of higher PTH levels as increased serum PTH levels may impair insulin signaling by inhibiting IRS-1 serine phosphorylation in adipocytes and reducing whole-body fat oxidation (15). However, we found that blood glucose levels affected

TABLE 3 Multiple stepwise regression analysis of preoperative PTH influencing factors.

Variables	SE	β	t	Р
Constant	9.262		12.667	<0.001
Pre_Ca ²⁺ (mmol/L)	4.509	-0.263	-10.229	<0.001
FFA (mmol/L)	1.856	0.171	7.746	<0.001
BMI (kg/m ²)	0.092	0.153	6.872	<0.001
TSH (μIU/mL)	0.18	0.057	2.654	0.008
ALB (g/L)	0.126	0.063	2.503	0.012
RBP (mg/L)	0.047	-0.058	-2.434	0.015
FT4 (pmol/L)	0.192	0.046	2.093	0.036

 β : Standardized Coefficient, Preoperative Ca²⁺(Pre_Ca²⁺).

both postoperative absolute PTH values and relative postoperative PTH reduction. Following thyroidectomy, most patients experience a varying degree of PTH decline. We observed that preoperative high glucose levels are a risk factor for both postoperative hypoparathyroidism and significant PTH reduction. This finding further highlights the complex and intricate interplay among blood glucose, PTH, and insulin, holding important implications for predicting the risk of postoperative hypoparathyroidism. Nevertheless, the mechanisms remain unclear and warrant further investigation in future studies.

The protective role of higher BMI is consistent with previous studies (16–19), though studies involving more than 2,000 patients remain relatively rare. Finel et al. found that although patients with BMI≥25 experience significantly longer surgical durations, the incidence of transient or permanent hypoparathyroidism does not show statistical significance (19). Based on statistical analysis of over 2,000 patients, our study identified BMI≥24 as a protective factor against hypoparathyroidism. Increased adipose tissue within the anatomical region, particularly within the parathyroid capsule, may contribute to improved blood supply to the parathyroid glands during surgery, providing a protective effect for patients with higher BMI (17). However, we believe the more crucial factor is that the

TABLE 4 Comparison of baseline characteristics in total thyroidectomy patients.

	Classified by the occurrence of hypoparathyroidism				Classified by the rate of decline			
Variables	Normal (n=364)	Hypoparathyroidism (n=404)	χ²/t/Z	Р	Mild decrease (n=576)	Significant decrease (n=192)	χ²/t/Z	Р
Sex,n (%)			11.773	<0.001			3.13	0.077
female	272 (74.7)	342 (84.7)			452 (78.5)	162 (84.4)		
male	92 (25.3)	62 (15.3)			124 (21.5)	30 (15.6)		
Age,n (%)			0.434	0.51			0.506	0.477
<45	169 (46.4)	178 (44.1)			256 (44.4)	91 (47.4)		
≥45	195 (53.6)	226 (55.9)			320 (55.6)	101 (52.6)		
BMI,n (%)			5.456	0.019			2.332	0.127
<24	132 (36.3)	180 (44.6)			225 (39.1)	87 (45.3)		
≥24	232 (63.7)	224 (55.4)			351 (60.9)	105 (54.7)		
TPOAb,n (%)			8.316	0.004			14.145	<0.001
<36	325 (89.3)	331 (81.9)			510 (88.5)	149 (77.6)		
≥36	39 (10.7)	73 (18.1)			66 (11.5)	43 (22.4)		
Erythrocyte (10^12/L)	4.43 (4.18,4.72)	4.38 (4.13,4.63)	-2.11	0.035	4.39 (4.16,4.68)	4.39 (4.14,4.68)	-0.563	0.573
Hemoglobin (g/L)	131 (123, 142)	128 (119.75, 137)	3.09	0.002	131 (122,140)	127 (117.5,135.25)	-3.206	0.001
FT3 (pmol/L)	4.23 (3.95, 4.56)	4.2 (3.92, 4.49)	1.30	0.194	4.22 (3.94,4.53)	4.18 (3.93,4.51)	-0.834	0.404
FT4 (pmol/L)	12.21 (11.22, 13.23)	12.2 (11.19, 13.21)	0.01	0.992	12.14 (11.15,13.2)	12.36 (11.44,13.34)	-1.856	0.063
TSH (μIU/mL)	1.67 (1.07,2.39)	1.7 (1.16,2.44)	-0.894	0.371	1.69 (1.16,2.43)	1.66 (1.08,2.3)	-0.724	0.469
TGAb (IU/mL)	16.5 (14,36.78)	17.1 (14.5,67.8)	-2.10	0.036	16.6 (14.2,47.72)	17.15 (14.47,69.82)	-1.203	0.229
TRAb (IU/L)	0.8 (0.8,0.8)	0.8 (0.8,0.8)	-0.99	0.321	0.8 (0.8,0.8)	0.8 (0.8,0.8)	-0.34	0.734
AST (U/L)	20 (16.75,23)	19 (16,22)	-1.58	0.114	19 (16,23)	19 (16,22)	-1.355	0.176
ALT (U/L)	16 (12,24)	15 (11,22)	-1.25	0.211	15 (12,23)	15 (11,22)	-0.763	0.446
TBA (μmol/L)	3.9 (2.5,6.23)	3.95 (2.8,6.2)	-0.47	0.64	3.9 (2.5,6.23)	4 (2.88,6.12)	-0.661	0.509
TP (g/L)	69.4±4.84	68.93±4.76	0.89	0.375	69.25±4.86	68.56±4.59	-1.512	0.13
ALB (g/L)	41.3 (39.27, 43.23)	40.7 (38.98, 42.7)	1.72	0.086	40.95 (39.2,43)	40.8 (39,42.8)	-0.827	0.409
TG (mmol/L)	1.23 (0.86,1.69)	1.15 (0.81,1.65)	-1.05	0.293	1.2 (0.85,1.65)	1.19 (0.8,1.71)	-0.003	0.998
TC (mmol/L)	4.7 (4.1,5.27)	4.71 (4.05,5.5)	-0.05	0.958	4.71 (4.1,5.37)	4.63 (3.99,5.48)	-0.601	0.548
HDL_C (mmol/L)	1.28 (1.06, 1.5)	1.31 (1.14, 1.5)	-1.07	0.287	1.32 (1.1,1.52)	1.25 (1.11,1.44)	-1.753	0.08
LDL_C (mmol/L)	2.95 (2.44,3.44)	2.94 (2.4,3.46)	-0.22	0.829	2.95 (2.45,3.44)	2.9 (2.37,3.57)	-0.407	0.684
FFA (mmol/L)	0.37 (0.26,0.51)	0.38 (0.27,0.51)	-0.50	0.62	0.37 (0.27,0.51)	0.39 (0.29,0.52)	-1.035	0.301
GLU (mmol/L)	4.53 (4.2, 4.91)	4.52 (4.16, 4.92)	-2.02	0.039	4.53 (4.18,4.91)	4.52 (4.19,4.93)	-0.408	0.683
CREA (µmol/L)	56.15 (49.27,64.23)	53.9 (48.8, 61)	2.05	0.04	55.5 (49.4,63.23)	53.45 (47.68,60)	-2.445	0.014
RBP (mg/L)	33.5 (29.3, 38.92)	32.2 (28.85, 38.12)	2.01	0.045	33.1 (29.1,38.52)	32.05 (28.9,37.92)	-1.116	0.264
Pre_Ca ²⁺ (mmol/L)	2.34 (2.28, 2.39)	2.33 (2.27, 2.38)	0.72	0.472	2.34 (2.28,2.39)	2.32 (2.26,2.38)	-2.35	0.019
Pre_PTH (pg/mL)	46.04 (37.06,56.8)	43.44 (34.25,55.52)	-2.41	0.016	42.94 (34.62,52.34)	52.08 (40.58,61.74)	-6.197	<0.001

Data are expressed as means ± SD or medians (interquantile range), Preoperative Ca²⁺ (Pre_Ca²⁺) Preoperative PTH (Pre_PTH).

increased adipose tissue surrounding the parathyroid glands acts as a buffer, reducing physical trauma to the glands and their blood vessels during surgical manipulation. This buffering effect may further lower the risk of parathyroid dysfunction.

To date, no studies have elucidated the effect of Retinol-Binding Protein(RBP) on PTH levels. Our data show a negative correlation between preoperative serum PTH levels and RBP, and univariate analysis identified high RBP levels as a risk factor for postoperative hypoparathyroidism. RBP is currently the only known specific transport protein for vitamin A (retinol). After retinol binds to RBP, it further forms a retinol-RBP-TTR complex with transthyretin (TTR), which transports retinol to target tissues (20). Retinoic acid (RA), the active metabolite of retinol, plays a crucial role in regulating cell proliferation and differentiation. Previous studies have confirmed that parathyroid cells are among the few specialized cell types equipped with a complete vitamin A metabolic pathway, expressing key proteins essential for intracellular retinol and retinoic acid metabolism. These include 9-cis-retinoic acid receptor (RXR), all-trans-retinoic acid receptor (RAR), cellular retinol-binding protein (CRBP type I), and cellular retinoic acid-binding proteins (CRABP types I and II) (21, 22).

Retinoic acid can inhibit the proliferation of parathyroid chief cells and significantly reduce PTH mRNA expression levels by activating nuclear receptor signaling pathways, thereby suppressing PTH secretion. Additionally, retinoic acid enhances the calcium sensitivity of parathyroid cells by shifting the calcium set point for PTH release to the left, allowing PTH secretion to be suppressed at lower blood calcium levels. The observed negative correlation between RBP levels and PTH levels in our study is likely due to RBP interfering with retinol metabolism (21, 23). Although these findings suggest that RBP may play a role in regulating parathyroid cell function, the exact mechanisms remain unclear and warrant further investigation.

Although Hashimoto's thyroiditis (HT) is widely recognized as a key risk factor for postoperative hypoparathyroidism and a predictor of incidental parathyroidectomy (24, 25), some studies have suggested no association between HT and postoperative hypoparathyroidism in patients undergoing total thyroidectomy (26, 27). Our study further demonstrated a positive correlation between postoperative serum PTH decline and TPOAb levels — a crucial marker for HT diagnosis aside from histological evidence indicating a close association between HT and postoperative serum PTH reduction. This finding aligns with other studies that have identified HT as an independent risk factor for hypoparathyroidism (5, 28, 29). Moreover, research has shown that TPOAb levels are closely correlated with the number of autoreactive lymphocytes infiltrating the thyroid gland. Higher TPOAb levels are associated with more severe thyroid destruction and fibrosis (30). We propose that long-term HT may lead to thyroid enlargement, resulting in a grayish appearance of the gland, hard in texture, and exert chronic compression on the parathyroid glands, potentially resulting in structural and functional alterations. Additionally, during surgery on HT patients, thyroid enlargement, increased hardness, and adhesions to surrounding tissues elevate the difficulty of dissection (31, 32). The increased vascularity of the thyroid can also cause intraoperative bleeding and obscure the surgical field (33, 34), further raising the risk of parathyroid injury. On the other hand, the heightened risk of parathyroid injury in HT patients may be linked to the intense inflammatory process. The dense fibrous capsule formed by inflammation may obscure parathyroid glands located within or near the capsule, making them harder to identify and increasing the likelihood of accidental resection (5, 28, 35).

Currently, whether sex factors influence hypoparathyroidism after thyroidectomy remains controversial (5, 36–38). Another key finding of our study is that sex is a significant factor influencing postoperative hypoparathyroidism, regardless of whether patients underwent total thyroidectomy or hemithyroidectomy with isthmusectomy. This finding is consistent with the systematic review by Edafe et al (4). However, the underlying mechanisms remain unclear. Anatomical and physiological studies suggest potential differences between male and female parathyroid glands. For example, autopsy studies have shown that male parathyroid glands may contain a higher proportion of stromal fat than those in females (39). Additionally, sex-related differences may exist in factors regulating monoclonal proliferation and mitosis in parathyroid tissue (37, 40).

Hormonal differences are another possible explanation. For instance, estrogen has been shown to regulate intestinal calcium absorption independently of 1,25(OH)₂D (41-43), contributing to the maintenance of serum Ca2+ levels. In vitro studies have confirmed the presence of estrogen receptors in the parathyroid glands, revealing a functional relationship between estrogen and the parathyroid, which can directly influence PTH secretion, DNA synthesis, and gene transcription (44-46). Meanwhile, the prevalence of HT in females is significantly higher than in males, with the male-to-female ratio being approximately 1:10 (47). As discussed above, HT has been established as an independent risk factor for parathyroid injury, which may be a key contributor to the observed sex-differences. The interplay of these factors may explain why female patients are more likely to experience postoperative serum PTH decline and related complications after thyroidectomy. It is worth noting that in this study, the BMI of male patients was significantly higher than that of female patients, suggesting that the protective effect observed in males may be partly attributable to their higher BMI.

Previous studies on the effect of age on postoperative hypoparathyroidism have yielded conflicting conclusions, which can be broadly categorized into three groups. Some studies suggest that older patients are more prone to developing postoperative hypoparathyroidism (6, 48), while others report that the complication is more common among young patients (26, 49, 50). Additionally, some studies have found no significant association between age and postoperative hypoparathyroidism (36, 51). Our study found that age had no significant impact on postoperative hypoparathyroidism or relative postoperative PTH reduction. This finding suggests that clinicians should focus more on other potential risk factors rather than relying solely on patient age to evaluate the risk of postoperative parathyroid dysfunction.

Lastly, we found a negative correlation between preoperative high hemoglobin levels and postoperative PTH decline. This may be

A. Classified by the Occurrence of Hypoparathyroidism after total thyroidectomy

Variables	OR(95%CI)		P
Sex	0.554(0.381-0.805)	-	0.002**
BMI	0.714(0.524-0.971)	-	0.032*
TPOAb	1.786(1.168-2.731)		● 0.007**
GLU	1.319(1.089-1.597)	-	0.005**
Pre_PTH	0.988(0.979-0.998)	•	0.013*
		0 0.5 1 1.5	2

B. Classified by the rate of decline after total thyroidectomy

Variables	OR(95%CI)		P
BMI	0.611(0.414-0.902)	-	0.013*
Hemoglobin	0.984(0.973-0.995)	•	0.003**
FT4	1.098(1.008-1.197)	•	0.033*
TPOAb	2.266(1.451-3.538)	──	<0.001**
HDL_C	0.426(0.229-0.792)	-	0.007**
GLU	1.234(1.024-1.488)	-	0.027*
Pre_PTH	1.032(1.021-1.043)	•	<0.001**
		0 0.5 1 1.5 2 2.5 OR(95% CI)	

C. Classified by the rate of decline after hemithyroidectomy with isthmusectomy

Variables	OR(95%CI)		P
Sex	0.558(0.380-0.819)	-	0.003**
TG	1.122(0.994-1.266)	-	0.064
Pre_Ca ²⁺	0.110(0.020-0.605)	-	0.011*
Pre_PTH	1.036(1.026-1.045)	•	<0.001**
		0 0.5 1 1.5 2 OR(95% CI)	

FIGURE 3

Multifactorial analysis of hypoparathyroidism after thyroidectomy. (A) Classified by the occurrence of hypoparathyroidism after total thyroidectomy. (B) Classified by the rate of postoperative PTH decline after total thyroidectomy. (C) Classified by the rate of postoperative PTH decline after hemithyroidectomy with isthmusectomy. Preoperative Ca²⁺ (Pre_Ca²⁺), Preoperative PTH (Pre_PTH).

because relatively higher hemoglobin levels help protect the parathyroid glands from ischemic and hypoxic injury during surgery. Moreover, hemoglobin may further reduce the risk of postoperative PTH decline by regulating microcirculation and improving local tissue metabolism (52). Therefore, assessing preoperative hemoglobin levels could serve as a potential indicator for predicting postoperative hypoparathyroidism, providing a new reference for perioperative management.

The strength of this study lies in its large sample size and comprehensive analysis, providing robust data support for exploring the relationship between preoperative indicators and postoperative hypoparathyroidism. Also, we developed a new threshold method to better evaluate the decline in postoperative parathyroid function. However, there are still certain limitations in this study. The retrospective single-center design may affect the generalizability of

the results. Moreover, this study did not consider the potential impact of magnesium levels on parathyroid function. Future studies should incorporate data from multiple centers, include a more diverse population, and assess additional relevant indicators to enhance the representativeness and applicability of the findings.

5 Conclusion

Our study indicates that preoperative serum PTH levels are positively correlated with FFA, BMI, TSH, and FT4, while negatively correlated with RBP and Ca²⁺. Higher preoperative blood glucose levels and HT are risk factors for hypoparathyroidism after total thyroidectomy, whereas BMI≥24 is a protective factor for postoperative hypoparathyroidism in both the two methods to define

TABLE 5 Comparison of baseline characteristics between mild and significant postoperative PTH decline in hemithyroidectomy with isthmusectomy patients.

Variables	Mild decrease (n=777)	Significant decrease (n=278)	χ^2/Z	р
Sex,n (%)			12.187	<0.001
female	577 (74)	235 (85)		
male	200 (26)	43 (15)		
Age,n (%)			0.935	0.334
<45	393 (51)	150 (54)		
≥45	384 (49)	128 (46)		
BMI, <i>n</i> (%)			0.122	0.726
<24	328 (42)	114 (41)		
≥24	449 (58)	164 (59)		
TPOAb,n (%)				
<36	667 (85.8)	238 (85.6)	0.003	0.524
≥36	110 (14.2)	40 (14.4)		
Erythrocyte (10 ¹² /L)	4.39 (4.13,4.7)	4.33 (4.06,4.56)	-2.925	0.003
Hemoglobin (g/L)	130 (121,141)	128 (119,136)	-2.889	0.004
FT3 (pmol/L)	4.24 (3.99,4.55)	4.17 (3.92,4.46)	-2.939	0.003
FT4 (pmol/L)	12.24 (11.33,13.11)	12.06 (11.32,13.2)	-0.471	0.638
TSH (μIU/mL)	1.68 (1.21,2.45)	1.85 (1.32,2.64)	-2.139	0.032
TGAb (IU/mL)	16.2 (14.1,25.6)	16.5 (14,41.4)	-0.022	0.983
TRAb (IU/L)	0.8 (0.8,0.8)	0.8 (0.8,0.8)	-1.295	0.195
AST (U/L)	19 (16,22)	18 (16,21)	-1.957	0.05
ALT (U/L)	15 (11,23)	15 (11,19.75)	-1.289	0.198
TBA (μmol/L)	3.9 (2.5,6.4)	3.9 (2.5,6.2)	-0.256	0.798
TP (g/L)	68.4 (65.4,71.8)	68.05 (65.43,71.47)	-0.322	0.748
ALB (g/L)	41.2 (39.5,43)	40.8 (38.92,42.6)	-1.952	0.051
TG (mmol/L)	1.16 (0.83,1.74)	1.08 (0.8,1.7)	-0.742	0.458
TC (mmol/L)	4.65 (4.06,5.31)	4.63 (4.09,5.2)	-0.242	0.809
HDL_C (mmol/L)	1.29 (1.09,1.54)	1.29 (1.14,1.47)	-0.218	0.827
LDL_C (mmol/L)	2.86 (2.4,3.38)	2.89 (2.43,3.39)	-0.011	0.991
FFA (mmol/L)	0.38 (0.28,0.52)	0.41 (0.29,0.54)	-1.67	0.095
GLU (mmol/L)	4.53 (4.2,4.93)	4.56 (4.26,4.89)	-0.635	0.525
CREA (µmol/L)	55.7 (49.6,63.6)	54.85 (49.5,61.03)	-1.641	0.101
RBP (mg/L)	33.5 (29.1,38.9)	32.75 (28,37.75)	-2.072	0.038
Pre_Ca ²⁺ (mmol/L)	2.33 (2.28,2.39)	2.3 (2.25,2.36)	-4.283	<0.001
Pre_PTH (pg/mL)	41.39 (34.38,52.84)	53.22 (40.02,64.41)	-8.341	<0.001

Preoperative Ca $^{2+}$ (Pre_Ca $^{2+}$), Preoperative PTH (Pre_PTH).

the decline of parathyroid function. Additionally, female is a risk factor for hypoparathyroidism after total or hemithyroidectomy with isthmusectomy. Higher preoperative hemoglobin levels and HDL-C are negatively correlated with the decline of PTH after total thyroidectomy.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Shandong Provincial Hospital Ethics Committee for Human Biomedical Research Rapid Ethical Review Approval Document. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from a by- product of routine care or industry. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

KL: Writing – review & editing, Writing – original draft. NW: Writing – original draft, Writing – review & editing. PZ: Writing – original draft, Writing – review & editing. BZ: Writing – review & editing, Writing – original draft, Writing – original draft, Writing – review & editing. YS: Writing – original draft, Writing – review & editing. CG: Writing – review & editing, Writing – original draft.

Funding

The author(s) declare financial support was received for the research and/or publication of this article. This work was supported

in part by the National Natural Science Foundation of China under Grant 82470822, in part by the Shandong Provincial Natural Science Foundation under Grants ZR2024MH307.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2025.1594781/full#supplementary-material

References

- 1. Orloff LA, Wiseman SM, Bernet VJ, Fahey TJ 3rd, Shaha AR, Shindo ML, et al. American thyroid association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. *Thyroid*. (2018) 28:830–41. doi: 10.1089/thy.2017.0309
- 2. Edafe O, Mech CE, Balasubramanian SP. Calcium, vitamin D or recombinant parathyroid hormone for managing post-thyroidectomy hypoparathyroidism. *Cochrane Database Syst Rev.* (2019) 5:CD012845. doi: 10.1002/14651858.CD012845.pub2
- 3. Frey S, Figueres L, Pattou F, Le Bras M, Caillard C, Mathonnet M, et al. Impact of permanent post-thyroidectomy hypoparathyroidism on self-evaluation of quality of life and voice: results from the national qoL-hypopara study. *Ann Surg.* (2021) 274:851–8. doi: 10.1097/SLA.0000000000005129
- 4. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. *Br J Surgery*. (2014) 101:307–20. doi: 10.1002/bjs.9384
- 5. Lu D, Tang E, Yin S, Zhu J, Mo H, Yi Z, et al. Factors in the occurrence and restoration of hypoparathyroidism after total thyroidectomy for thyroid cancer patients with intraoperative parathyroid autotransplantation. *Front Endocrinol (Lausanne)*. (2022) 13:963070. doi: 10.3389/fendo.2022.963070
- 6. Cho JN, Park WS, Min SY. Predictors and risk factors of hypoparathyroidism after total thyroidectomy. *Int J Surg.* (2016) 34:47–52. doi: 10.1016/j.ijsu.2016.08.019
- 7. Ning K, Yu Y, Zheng X, Luo Z, Jiao Z, Liu X, et al. Risk factors of transient and permanent hypoparathyroidism after thyroidectomy: a systematic review and meta-analysis. *Int J Surg.* (2024) 110:5047-62. doi: 10.1097/JS9.000000000001475
- 8. Ahlstrom T, Hagstrom E, Larsson A, Rudberg C, Lind L, Hellman P. Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. *Clin Endocrinol (Oxf)*. (2009) 71:673–8. doi: 10.1111/j.1365-2265.2009.03558.x

- 9. Babic Leko M, Pleic N, Gunjaca I, Zemunik T. Environmental factors that affect parathyroid hormone and calcitonin levels. *Int J Mol Sci.* (2021) 23(1):44. doi: 10.3390/ijms23010044
- 10. Yuan TJ, Chen LP, Pan YL, Lu Y, Sun LH, Zhao HY, et al. An inverted U-shaped relationship between parathyroid hormone and body weight, body mass index, body fat. *Endocrine Jun.* (2021) 72:844–51. doi: 10.1007/s12020-021-02635-y
- 11. Danese VC, Pepe J, Ferrone F, Colangelo L, De Martino V, Nieddu L, et al. The mutual interplay between bone, glucose and lipid metabolism: the role of vitamin D and PTH. *Nutrients*. (2023) 15(13):2998. doi: 10.3390/nu15132998
- 12. Mihai R, Thakker RV. MANAGEMENT OF ENDOCRINE DISEASE: Postsurgical hypoparathyroidism: current treatments and future prospects for parathyroid allotransplantation. *Eur J Endocrinol.* (2021) 184:R165–75. doi: 10.1530/EJE-20-1367
- 13. Procopio M, Barale M, Bertaina S, Sigrist S, Mazzetti R, Loiacono M, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. *Endocrine*. (2014) 47:581–9. doi: 10.1007/s12020-013-0091-z
- 14. Wareham NJ, Byrne CD, Carr C, Day NE, Boucher BJ, Hales CN. Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality. *Metabolism.* (1997) 46:1171–7. doi: 10.1016/s0026-0495(97)90212-2
- 15. Chang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. *Mol Cell Endocrinol.* (2009) 307:77–82. doi: 10.1016/j.mce.2009.03.024
- 16. Soelling SJ, Mahvi DA, Liu JB, Sheu NO, Doherty G, Nehs MA, et al. Impact of obesity on risk of hypocalcemia after total thyroidectomy: targeted national surgical quality improvement program analysis of 16,277 patients. *J Surg Res.* (2023) 291:250–9. doi: 10.1016/j.jss.2023.06.006
- 17. Mahvi DA, Witt RG, Lyu HG, Gawande AA, Nehs MA, Doherty GM, et al. Increased body mass index is associated with lower risk of hypocalcemia in total thyroidectomy patients. *J Surg Res.* (2022) 279:240–6. doi: 10.1016/j.jss.2022.06.002
- 18. Milone M, Musella M, Conzo G, Campana G, De Filippo D, Coretti G, et al. Thyroidectomy in high body mass index patients: A single center experience. *Int J Surg.* (2016) 28 Suppl 1:S38–41. doi: 10.1016/j.ijsu.2015.12.054
- 19. Finel JB, Mucci S, Branger F, Venara A, Lenaoures P, Rodien P, et al. Thyroidectomy in patients with a high BMI: a safe surgery? *Eur J Endocrinol.* (2014) 171:99–105. doi: 10.1530/EJE-14-0063
- 20. Nono Nankam PA, Bluher M. Retinol-binding protein 4 in obesity and metabolic dysfunctions. *Mol Cell Endocrinol.* (2021) 531:111312. doi: 10.1016/j.mce.2021.111312
- 21. Hellman P, Liu W, Westin G, Torma H, Akerstrom G. Vitamin D and retinoids in parathyroid glands (review). *Int J Mol Med.* (1999) 3:355–61. doi: 10.3892/iimm 3.4.355
- 22. Wong CK, Lai T, Holly JM, Wheeler MH, Stewart CE, Farndon JR. The effects of retinoic acid on the insulin-like growth factor axis in primary tissue culture from hyperparathyroidism. *World J Surg.* (2006) 30:714–20. doi: 10.1007/s00268-005-0340-2
- 23. Liu W, Ridefelt P, Akerstrom G, Hellman P. Differentiation of human parathyroid cells in culture. *J Endocrinol.* (2001) 168:417–25. doi: 10.1677/joe.0.1680417
- 24. Abboud B, Sleilaty G, Braidy C, Zeineddine S, Ghorra C, Abadjian G, et al. Careful examination of thyroid specimen intraoperatively to reduce incidence of inadvertent parathyroidectomy during thyroid surgery. *Arch Otolaryngol Head Neck Surg.* (2007) 133:1105–10. doi: 10.1001/archotol.133.11.1105
- 25. Khairy GA, Al-Saif A. Incidental parathyroidectomy during thyroid resection: incidence, risk factors, and outcome. *Ann Saudi Med.* (2011) 31:274–8. doi: 10.4103/0256-4947.81545
- 26. Qin Y, Sun W, Wang Z, Dong W, He L, Zhang T, et al. A meta-analysis of risk factors for transient and permanent hypocalcemia after total thyroidectomy. *Front Oncol.* (2021) 10:614089. doi: 10.3389/fonc.2020.614089
- 27. Shih ML, Lee JA, Hsieh CB, Yu JC, Liu HD, Kebebew E, et al. Thyroidectomy for hashimoto's thyroiditis: complications and associated cancers. *Thyroid.* (2008) 18:729–34. doi: 10.1089/thy.2007.0384
- 28. McManus C, Luo J, Sippel R, Chen H. Is thyroidectomy in patients with Hashimoto thyroiditis more risky? J Surg Res. (2012) 178:529–32. doi: 10.1016/j.jss.2012.09.017
- 29. Thomusch O, Sekulla C, Billmann F, Seifert G, Dralle H, Lorenz K, et al. Risk profile analysis and complications after surgery for autoimmune thyroid disease. *Br J Surg.* (2018) 105:677–85. doi: 10.1002/bjs.10770
- 30. Li Y, Wang Y, Wu Q, Hu B. Papillary thyroid microcarcinoma co-exists with Hashimoto's thyroiditis: Is strain elastography still useful? *Ultrasonics*. (2016) 68:127–33. doi: 10.1016/j.ultras.2016.02.013

- 31. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. *Autoimmun Rev.* (2014) 13:391–7. doi: 10.1016/j.autrev.2014.01.007
- 32. Memeh K, Ruhle B, Vaghaiwalla T, Kaplan E, Keutgen X, Angelos P. Thyroidectomy for euthyroid patients with Hashimoto thyroiditis and persisting symptoms: A cost-effectiveness analysis. *Surgery*. (2021) 169:7–13. doi: 10.1016/j.surg.2020.03.028
- 33. Zhang QY, Ye XP, Zhou Z, Zhu CF, Li R, Fang Y, et al. Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis. *Nat Commun.* (2022) 13(1):775. doi: 10.1038/s41467-022-28120-2
- 34. Wu G. Ultrasonography in diagnosis of Hashimoto rsquo s thyroiditis. Front Biosci. (2016) 21:1006–12. doi: 10.2741/4437
- 35. Gan X, Feng J, Deng X, Shen F, Lu J, Liu Q, et al. The significance of Hashimoto's thyroiditis for postoperative complications of thyroid surgery: a systematic review and meta-analysis. *Ann R Coll Surg Engl.* (2021) 103:223–30. doi: 10.1308/rcsann.2020.7013
- 36. Lale A, Oz B, Akcan AC, Sozuer EM, Arikan TB, Gok M. Determination of risk factors causing hypocalcaemia after thyroid surgery. *Asian J Surg.* (2019) 42:883–9. doi: 10.1016/j.asjsur.2018.12.009
- 37. Su A, Wang B, Gong Y, Gong R, Li Z, Zhu J. Risk factors of hypoparathyroidism following total thyroidectomy with central lymph node dissection. *Med (Baltimore)*. (2017) 96:e8162. doi: 10.1097/MD.000000000008162
- 38. Yazicioglu MO, Yilmaz A, Kocaoz S, Ozcaglayan R, Parlak O. Risks and prediction of postoperative hypoparathyroidism due to thyroid surgery. *Sci Rep.* (2021) 11:11876. doi: 10.1038/s41598-021-91277-1
- 39. Dekker A, Dunsford HA, Geyer SJ. The normal parathyroid gland at autopsy: the significance of stromal fat in adult patients. *J Pathol.* (1979) 128:127–32. doi: 10.1002/path.1711280303
- 40. Sands NB, Payne RJ, Cote V, Hier MP, Black MJ, Tamilia M. Female gender as a risk factor for transient post-thyroidectomy hypocalcemia. *Otolaryngol Head Neck Surg.* (2011) 145:561–4. doi: 10.1177/0194599811414511
- 41. Nie X, Jin H, Wen G, Xu J, An J, Liu X, et al. Estrogen regulates duodenal calcium absorption through differential role of estrogen receptor on calcium transport proteins. *Dig Dis Sci.* (2020) 65:3502–13. doi: 10.1007/s10620-020-06076-x
- 42. Pérez AV, Picotto G, Carpentieri AR, Rivoira MA, Peralta López ME, Tolosa de Talamoni NG. Minireview on regulation of intestinal calcium absorption. *Digestion*. (2008) 77:22–34. doi: 10.1159/000116623
- 43. Christakos S, Dhawan P, Porta A, Mady LJ, Seth T. Vitamin D and intestinal calcium absorption. *Mol Cell Endocrinol.* (2011) 347:25–9. doi: 10.1016/j.mce.2011.05.038
- 44. Duarte B, Hargis GK, Kukreja SC. Effects of estradiol and progesterone on parathyroid hormone secretion from human parathyroid tissue*. *J Clin Endocrinol Metab.* (1988) 66:584–7. doi: 10.1210/jcem-66-3-584
- 45. Greenberg C, Kukreja SC, Bowser EN, Hargis GK, Henderson WJ, Williams GA. Parathyroid hormone secretion: Effect of estradiol and progesterone. *Metabolism*. (1987) 36:151–4. doi: 10.1016/0026-0495(87)90009-6
- 46. Haglund F, Rosin G, Nilsson IL, Juhlin CC, Pernow Y, Norenstedt S, et al. Tumour nuclear oestrogen receptor beta 1 correlates inversely with parathyroid tumour weight. *Endocrine Connections*. (2015) 4:76–85. doi: 10.1530/ec-14-0109
- 47. Ralli M, Angeletti D, Fiore M, D'Aguanno V, Lambiase A, Artico M, et al. Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential Malignant transformation. *Autoimmun Rev.* (2020) 19:102649. doi: 10.1016/j.autrev.2020.102649
- 48. Erbil Y, Barbaros U, Temel B, Turkoglu U, Işsever H, Bozbora A, et al. The impact of age, vitamin D3 level, and incidental parathyroidectomy on postoperative hypocalcemia after total or near total thyroidectomy. *Am J Surgery*. (2009) 197:439–46. doi: 10.1016/j.amjsurg.2008.01.032
- 49. Takahashi T, Yamazaki K, Shodo R, Ueki Y, Horii A. Actual prevalence of hypoparathyroidism after total thyroidectomy: a health insurance claims-database study. *Endocrine*. (2022) 78:151–8. doi: 10.1007/s12020-022-03153-1
- 50. Torabi SJ, Avery JM, Salehi PP, Lee Y. Risk factors and effects of hypocalcemia prior to discharge following thyroidectomy. *Am J Otolaryngol.* (2020) 41(3):102420. doi: 10.1016/j.amjoto.2020.102420
- 51. Eismontas V, Slepavicius A, Janusonis V, Zeromskas P, Beisa V, Strupas K, et al. Predictors of postoperative hypocalcemia occurring after a total thyroidectomy: results of prospective multicenter study. *BMC Surgery*. (2018) 18(1):55. doi: 10.1186/s12893-
- 52. Premont RT, Reynolds JD, Zhang R, Stamler JS. Role of nitric oxide carried by hemoglobin in cardiovascular physiology. *Circ Res.* (2020) 126:129–58. doi: 10.1161/circresaha.119.315626